Expression of Transforming Growth Factor-Beta (TGF-Beta) in Prostate Cancer Cell Progression

Abstract

The objective of the current Phase II proposal is to test a novel TGF-beta based gene therapy in prostate cancer. During the Phase I study, our findings demonstrate that TGF-beta over-production by the tumor cells was immunosuppressive. In the Phase II research we proposed to render host immune cells insensitive to TGF-beta by introducing a domina negative TGF-beta type II receptor (dnTBRII) to host immune cells. Three tasks were proposed. In Task 1, we proposed to generate the dnTBRII construct with green fluoresce protein (GFP) as a selectable marker and introduce the construct into host's bone marro cells. In Task 2, we proposed to test if immune cells will escape the negative selection in the thymus. In Task 3, we proposed to test whether or not the TGF-beta insensitive immune cells will mediate anti-tumor activity.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 2002
Accession Number
ADA412198

Entities

People

  • Chung Lee

Organizations

  • Northwestern University

Tags

DTIC Thesaurus Topics

  • Blood
  • Body Weight
  • Bone Marrow Cells
  • Cardiovascular System
  • Cell Physiological Processes
  • Cells
  • Chemistry
  • Gene Therapy
  • Growth Factors
  • Hematopoiesis
  • Lymphatic System
  • Lymphocytes
  • Myeloid Cells
  • Peptide Growth Factors
  • Prostate Cancer
  • Stem Cells
  • Tissues

Readers

  • Molecular Biology and Genetics
  • Molecular Genetics
  • Oncology

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech